Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States of America.
Hematology and Oncology Department, Baylor College of Medicine, Houston, Texas, United States of America.
PLoS One. 2022 May 4;17(5):e0267584. doi: 10.1371/journal.pone.0267584. eCollection 2022.
Patients with cancer often have compromised immune system which can lead to worse COVID-19 outcomes. The purpose of this study is to assess the association between COVID-19 outcomes and existing cancer-specific characteristics.
Patients aged 18 or older with laboratory-confirmed COVID-19 between June 1, 2020, and December 31, 2020, were identified (n = 314 004) from the Optum® de-identified COVID-19 Electronic Health Record (EHR) derived from more than 700 hospitals and 7000 clinics in the United States. To allow sufficient observational time, patients with less than one year of medical history in the EHR dataset before their COVID-19 tests were excluded (n = 42 365). Assessed COVID-19 outcomes including all-cause 30-day mortality, hospitalization, ICU admission, and ventilator use, which were compared using relative risks (RRs) according to cancer status and treatments.
Among 271 639 patients with COVID-19, 18 460 had at least one cancer diagnosis: 8034 with a history of cancer and 10 426 with newly diagnosed cancer within one year of COVID-19 infection. Patients with a cancer diagnosis were older and more likely to be male, white, Medicare beneficiaries, and have higher prevalences of chronic conditions. Cancer patients had higher risks for 30-day mortality (RR 1.07, 95% CI 1.01-1.14, P = 0.028) and hospitalization (RR 1.04, 95% CI 1.01-1.07, P = 0.006) but without significant differences in ICU admission and ventilator use compared to non-cancer patients. Recent cancer diagnoses were associated with higher risks for worse COVID-19 outcomes (RR for mortality 1.17, 95% CI 1.08-1.25, P<0.001 and RR for hospitalization 1.10, 95% CI 1.06-1.14, P<0.001), particularly among recent metastatic (stage IV), hematological, liver and lung cancers compared with the non-cancer group. Among COVID-19 patients with recent cancer diagnosis, mortality was associated with chemotherapy or radiation treatments within 3 months before COVID-19. Age, black patients, Medicare recipients, South geographic region, cardiovascular, diabetes, liver, and renal diseases were also associated with increased mortality.
Individuals with cancer had higher risks for 30-day mortality and hospitalization after SARS-CoV-2 infection compared to patients without cancer. More specifically, patients with a cancer diagnosis within 1 year and those receiving active treatment were more vulnerable to worse COVID-19 outcomes.
癌症患者的免疫系统往往受损,这可能导致更严重的 COVID-19 后果。本研究旨在评估 COVID-19 结局与现有癌症特异性特征之间的关联。
从美国 700 多家医院和 7000 多家诊所的 Optum®去识别 COVID-19 电子健康记录(EHR)中确定了 2020 年 6 月 1 日至 2020 年 12 月 31 日期间实验室确诊 COVID-19 的年龄在 18 岁或以上的患者(n=314004)。为了允许有足够的观察时间,排除了在 COVID-19 检测前 EHR 数据集中病史不足 1 年的患者(n=42365)。使用相对风险(RR)根据癌症状态和治疗方法比较了包括全因 30 天死亡率、住院、重症监护病房(ICU)入院和呼吸机使用在内的 COVID-19 结局。
在 271639 例 COVID-19 患者中,有 18460 例至少有一种癌症诊断:8034 例有癌症病史,10426 例在 COVID-19 感染后一年内新诊断出癌症。癌症患者年龄较大,更可能是男性、白人、医疗保险受益人,且更常见慢性疾病。与非癌症患者相比,癌症患者的 30 天死亡率(RR 1.07,95%CI 1.01-1.14,P=0.028)和住院率(RR 1.04,95%CI 1.01-1.07,P=0.006)更高,但 ICU 入院率和呼吸机使用率没有显著差异。最近的癌症诊断与更差的 COVID-19 结局相关(死亡率 RR 1.17,95%CI 1.08-1.25,P<0.001 和住院率 RR 1.10,95%CI 1.06-1.14,P<0.001),尤其是与非癌症组相比,近期转移性(IV 期)、血液学、肝脏和肺癌患者。在 COVID-19 伴有近期癌症诊断的患者中,死亡率与 COVID-19 前 3 个月内的化疗或放疗治疗有关。年龄、黑人患者、医疗保险受益人、南部地理区域、心血管疾病、糖尿病、肝脏和肾脏疾病也与死亡率增加有关。
与无癌症患者相比,SARS-CoV-2 感染后癌症患者的 30 天死亡率和住院率更高。更具体地说,在 1 年内诊断出癌症的患者和正在接受积极治疗的患者更容易出现更严重的 COVID-19 结局。